Binary expression is a powerful strategy for regulating the expression of an effector transgene for the purpose of investigating the develop ment or function of cells and tissues in multicellular organisms. In such a strategy, one transgene contains a specific promoter driv ing an exogenous transcription factor, whereas the other transgene uses a promoter that is specifically activated only by the introduced transcription factor. An additional layer of control is afforded if the transcription factor itself can be specifically inhibited by an exogenous element. The yeast GAL4 system is such a repressible binary expression system, and it has revolutionized experimental manipulations in flies 1,2 . The GAL4 transcription factor binds to an upstream activation sequence (UAS) to induce expression of a reporter transgene (UAS-geneX) (where geneX is any gene of interest). Only when GAL4 and UAS-geneX are in the same animal is geneX expressed in the GAL4 expression pattern. Thousands of GAL4 lines have been characterized for tissue and developmental expression patterns in Drosophila, and can be used in combina tion with thousands of effector lines. Effector lines range from cell markers (e.g., membranetagged GFP) to signaling molecules (e.g., activated Ras) to inhibitory molecules (e.g., neurotoxins or RNAi constructs). Furthermore, GAL4 activity can be inhibited by GAL80, a natural suppressor of GAL4 3 . Thus, when GAL80 is co expressed with GAL4, UAS-geneX reporters are silent. This allows for further effector refinement, including the Mosaic Analysis with a Repressible Cell Marker (MARCM) technique 3 . The combination of the three GAL4 components (GAL4, UAS-geneX and GAL80) allows for a rich diversity of experimental investigations.
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Nonetheless, the GAL4 system has its limitations. UAS-geneX effectors can only be expressed in the single population of cells defined by GAL4. In complex cellular organisms, it is often desir able to express an effector in a fraction of a cellular population, and then examine the effects on the other population of cells. Likewise, one might want to differentially label and manipulate two different types of tissues-neurons labeled with GFP and glia labeled with red fluorescent protein (RFP). Such techniques would be invalu able for determining noncellular autonomous effects (such as ligand/receptor interactions).
We have recently characterized the Q system for these and other purposes 4 ; the protocol described here is based on this previous work. The Q system uses genes from the qa gene cluster of the filamentous fungus Neurospora crassa. This gene cluster, consisting of seven genes, is required for the catabolism of quinic acid (quinate) under conditions of limited glucose levels [5] [6] [7] [8] [9] . This gene cluster con tains two regulatory genes: qa-1f (encoding a protein of 816 aa) and qa-1s (encoding a protein of 918 aa). qa1f (shortened as QF hereafter) is a transcription factor, and qa1s (shortened as QS hereafter) is a repressor of QF. The other five genes in the qa gene cluster encode enzymes or cofactors required for the catabolism of quinic acid. The promoters for the seven qa genes in Neurospora contain binding sites for QF, and expression of the qa genes can be induced by the QF transcription factor. The binding site for QF is the sequence '5′GGRTAARYRYTTATCC3′' (R is A/G, Y is C/T). Under normal growth conditions in which glucose is high, QS binds to and inhibits QF, and prevents expression of the qa gene cluster. However, when glucose is limiting and quinic acid is present, quinic acid binds to and inhibits QS. This releases QF from QS suppression, allowing QF to induce expression from the qa gene cluster. This results in the expression of the factors required for the catabolism of quinic acid as an energy source. In effect, the catabolite (quinic acid) controls expression of the genes required for its catabolism.
be achieved by using quinic acid and QS expression (Figs. 1c and 4). However, a key experimental advantage is obtained when the Q repressible binary system is used in conjunction with the GAL4repressible binary system. Figure 2 shows some of the pos sible applications achievable. Highlighted is the ability to define intersectional expression patterns, whereby finer precision of tis sue manipulations can be achieved (Figs. 5-8 ). In addition, the Q system can be used for MARCM analysis (Fig. 9) , which has a vari ety of in vivo applications 3, [10] [11] [12] [13] . As the Q system and GAL4 system function independently in vivo 4 , QMARCM and GAL4MARCM can be coupled to the same mitotic event. As such, an unlabeled progenitor cell would give rise by mitosis to one cell that is posi tively labeled by the Q system (as it lacks the QS repressor) and a sister cell that is positively labeled by the GAL4 system (as it lacks the GAL80 repressor). This is called 'coupled MARCM' , as the seg regation of the QS and GAL80 suppressors is coupled to the same mitotic event (Fig. 10) . This allows for the differential marking and manipulation of all progeny from a single mitotic event. If segrega tion of the QS and GAL80 suppressor were not coupled to the same mitotic event, then the cell progeny could independently be labeled or unlabeled by the GAL4 or Q system. This is called 'independent double MARCM' (Fig. 2) .
Comparisons with other methods Binary expression systems. The bacterial LexA/LexAop binary expression system has also been used to express effectors independently of GAL4 (ref. 14) . LexA contains a DNAbinding domain specific for the LexA operator (LexAop), yet it does not contain a transcriptional activation domain. In Drosophila, LexA is either fused to the viral acidic activation domain VP16 or the GAL4 activation domain (GAD). The LexAVP16 protein is insen sitive to GAL80, whereas the LexAGAD protein can be inhibited by GAL80. The LexA/LexAop system does not contain an endogenous suppressor, and hence cannot be used to generate some intersec tional expression patterns or for GAL4independent MARCM analysis. The LexAop-geneX reporter also has a higher basal level of expression compared with UAS-geneX or QUAS-geneX report ers 4 . Nonetheless, recent progress has been made to optimize the LexA/LexAop binary expression system for use in vivo 15, 16 .
Intersectional expression patterns. Limiting GAL4 expression patterns can also be achieved by expressing GAL80 in the tissue of interest 3, 17 . However, GAL80 expression patterns are difficult to determine, and GAL80 levels need to be higher than GAL4 for effec tive suppression. This can make it difficult to precisely define the resulting GAL4 expression pattern. A better approach, as detailed in Figure 2 and Step 7A of the PROCEDURE, is to use a binary expres sion system to drive GAL80 expression. Similarly, the LexA/LexAop system could be used to refine GAL4 expression patterns. In this case, LexA-VP16 would be used to drive LexAop-GAL80. However, given the lack of an independent repressor of LexA, the reciprocal experiment (using GAL4 to limit LexAop-geneX reporter expres sion) is not possible. This approach is possible using the Q system (Step 7B, Fig. 5b) .
Limiting expression patterns to overlapping subsets is also achieved by using the 'split GAL4' method, in which GAL4 is split into two parts-one part containing the DNAbinding domain and the other part containing the activation domain 18 . The two GAL4 components can be reconstituted in vivo by the addition of leucine zippers to the split GAL4 proteins. This technique can achieve precise intersectional expression patterns 18 . However, split GAL4 cannot use existing characterized GAL4 lines for intersec tional expression, the reconstituted GAL4 is not as robust as the original GAL4, and split GAL4 transgenes are not useful for many other purposes (in contrast to a new QF reagent that can be used for binary expression or MARCM experiments).
Mosaic labeling methods.
Coupled MARCM allows the labeling of all progeny from a single mitotic event. It can also be used for independent gain and lossoffunction genetic manipulations of both progeny. A number of other techniques also allow for the marking of both sister progeny.
'Dual expression control MARCM' uses LexA-GAD (the LexA DNAbinding domain fused to the GAL4 activation domain) in conjunction with GAL4based MARCM to visualize progeny from a cell division 14 . This technique allows labeling of different populations of cells (one labeled by the LexA driver and the other by the GAL4 driver) that arise from a common progeni tor. However, as both LexA-GAD and GAL4 are suppressed by GAL80, this prevents labeling and manipulation of all progeny from a cell division. This technique has been used successfully for lineage analysis of certain neuronal populations 14, 19 . 'Twinspot MARCM' uses UASinverse repeat (UAS-IR) transgenes as the source of repressors against two different fluores cent proteins. Similar in design to coupled MARCM, which uses the differential loss of tubP-GAL80 and tubP-QS (each driven by the αtubulin promoter), twinspot MARCM follows the coupled loss of the UAS-IR repressors 20 . This creates two sibling cells, each losing one of the RNAi repressor genes. Twinspot MARCM is simpler in design than coupled MARCM (as it uses fewer transgenes). However, both prog eny are labeled by the same GAL4 driver, which could miss labeling of a cell progeny that lies outside this expression pattern. In addition, as the system is based on GAL4 only, cell progeny cannot be independently manipulated. Nonetheless, this technique is a powerful method for resolving the lineage pattern of a GAL4 expression pattern 20, 21 . 'Twinspot generator' (TSG) does not use a binary expression system, but instead places two split chimeric fluorescent pro teins on the same chromosome arm in trans 22 . On FLPase recombination enzyme/FLPase recognition target (FLP/FRT)mediated recombination, the two fluorescent proteins are reconstituted and can be segregated to daughter cells. This is similar in design to the mouse mosaic analysis system with double markers (MADM) system for mosaic analysis 23 . The advan tage of the TSG method over other methods that use a repress ible binary system is the ability to examine clones shortly after clonal induction, as there is no perdurance of a repressor molecule. However, a major limitation is low marker expression as a result of the lack of binary systembased amplification. In addition, both markers are driven by a ubiquitous promoter, which severely limits the utility for tracking complex lineages. As TSG does not use a repressible binary system, cell progeny cannot be easily manipu lated by effector transgene expression.
Limitations of the Q system. As the Q system has only been recently introduced, a number of Q reagents, such as QUAS-geneX effectors or promoter-QF lines, remain to be generated. However, as more studies use the Q system, the availability of useful rea gents will grow. Alternatively, cases in which the GAL4 system is not sufficient, the LexA/LexAop system could be used if LexA system reagents have already been generated and validated for a tissue of interest, and experimental designs do not require an endogenous LexA suppressor. 
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Full body . These constructs differ in their 3′ transcriptional terminators. SV40 terminators lead to increased mRNA stability and higher protein expression. We have found that, in most cases, this increased protein level is not necessary or desirable when generating QF constructs because of the potential toxicity of high QF expression in asyetunidentified tissues. We therefore recommend that the pattB-QF-hsp70 construct be used for routine enhancer and promoter cloning.
Subset of tissues
There are three basic strategies for generating QF transgen ics using previously characterized expression patterns. The first involves the cloning of gene promoters. In many cases, an enhancer and promoter region will be the genomic region immediately upstream of the ATG start site of a gene up to the preceding gene 24 . A PCR reaction that introduces flanking BamHI and EcoRI restric tion sites can be used to amplify this genomic region for placement into the pattB-QF-hsp70 construct.
The second strategy to generate QF expression patterns of inter est is to clone the genomic region associated with enhancer trap insertions. The expression pattern of an enhancer trap could be mimicked by cloning a large genomic region immediately preced ing the insertion site of an enhancer trap 4, 11, 25 . In this case, a pro moter would also need to be included, such as either the Pelement promoter or the Drosophila synthetic core promoter (DSCP) 26 , with the QF-hsp70 cassette following the cloned genomic region.
When the above two approaches fail to recapitulate the expres sion pattern of interest, a third strategy is to clone a larger genomic region associated with the gene or enhancer trap insertion. Bacterial artificial chromosome (BAC) recombineering could be used to insert a promoter-QF-hsp70 cassette into a larger genomic region (20 or 80 kb) to increase the likelihood of recapitulating a complex regulatory locus 27 . These BAC resources are compatible with PhiC31 integra tion for the generation of transgenic animals. The BAC constructs contain an attB site, and by using PhiC31 integrase, they allow
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Figure 3 | Crossing scheme for tissue-specific QS suppression of QF. To simplify analysis of QS suppression on a QF-induced expression pattern, the QUAS-geneX reporter (QUAS-mtdT-3xHA) is recombined with P1-QF. Crossing this stable expression line with a P2-QS fly and selecting against the CyO balancer will result in progeny that have a subset of tissues no longer expressing the QUAS-geneX reporter. This can be directly compared with the original expression pattern. 
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Figure 4 | Crossing scheme for ubiquitous QS-mediated suppression of QF coupled with quinic acid treatment. Ubiquitous QS expression is achieved by using a tubulin promoter to drive QS (tubP-QS). Crossing tubP-QS with a P1-QF, QUAS-geneX recombinant and selecting against the CyO balancer will result in a progeny that no longer expresses the QUAS-geneX effector in any tissues. This QS-mediated suppression can be inhibited by feeding developing flies quinic acid or by feeding adult flies quinic acid. If treated with quinic acid, the QUAS-geneX reporter induced by P1-QF will be expressed. Differing levels of QS suppression can be achieved by altering the concentration of quinic acid fed to the flies. genomic insertion of large constructs into attP sites that have been placed at random locations in the Drosophila genome 28, 29 . In some cases, generating promoter-QF transgenic lines might be dif ficult, especially for constructs that would result in widespread expres sion of QF. This could be due to QF being more toxic than GAL4. To reduce QF expression (and potential QF toxicity), the QF cDNA has been codon nonoptimized for Drosophila expression. This allows for the generation of promoter-QF constructs that were previously difficult to generate, such as a panneuronal synaptobrevin-QF (C.J.P., unpub lished data). Efforts are also underway to modify the QF gene to reduce its toxicity when broadly expressed (C.J.P., unpublished data).
In addition, success rates for generating QF transgenic lines can be improved when using Pelement or piggyBacbased vectors instead of attB vectors (C.J.P., unpublished data). Alternative QF coding variants and QF cloning vectors that use piggyBac or Pelements are available from the authors on request. Table 2 ) can be mobilized by crossing with a stable Pelement trans posase (e.g., ∆2-3, Bloomington Stock no. 1798) to generate addi tional QF lines with new expression patterns. A small screen of ~25 lines has already identified QF enhancer trap lines that label trachea (ET14-QF), glia (ET31-QF), imaginal discs (ET40-QF) and many tissues including neuronal and epithelial (ET49-QF) tissues.
Generation of QF enhancer trap lines.
QF enhancer traps (and occasionally promoter-QF transgenes) can show tracheal expression, especially if the trapped enhancers are weak. This is likely to be due to a cryptic weak tracheal enhancer in the QF coding sequence. Constructs that use QF coding variants (and no longer contain the cryptic tracheal enhancer) show decreased or no tracheal expression in enhancer traps (C.J.P., unpublished data). In addition, tracheal-promoter-QS transgenic lines can be used to inhibit tracheal QFinduced reporter expression (C.J.P., unpublished data). These reagents are available from the authors on request. Table 2 ). To simplify the generation of additional QUAS-geneX transgenic flies, the pQUAST vector (Supplementary Table 1) contains the same mul ticloning site as the pUAST vector (EcoRIBglIINotISacIIXhoI KpnIXbaI), which allows for easy exchange of inserts between pUAST and pQUAST vectors. If the pUAST-geneX plasmid is not available, genomic DNA from flies containing the UAS-geneX transgene can be used as the source of the geneX insert 4 . By using Pelement-based transgenesis 30 , many independent insertions of the same QUAS-geneX construct will be generated. It is often useful to keep a single transgenic line on each of the three Figure 6 | Crossing scheme for GAL4 NOT QF intersectional experiments. For this NOT intersectional strategy to work, four components (P1-QF, P2-GAL4, UAS-geneX and QUAS-GAL80) need to be combined into a fly. In this example, a GAL4 NOT intersectional-ready female fly is represented. This fly contains a P2-GAL4 line recombined with a UAS-mCD8-GFP marker, as well as the QUAS-GAL80 transgene on the third chromosome. Crossing this stock to any QF line and selecting against the balancers will result in progeny that have reduced GAL4 expression based on the QF expression pattern. This simplifies the experimental setup for testing the intersectional results for many different QF lines.
Generation of QUAS-geneX effector lines. Another important Q sys tem reagent is the QFinducible reporter, QUAS-geneX. A number of QUAS-geneX transgenic flies are available (Supplementary
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Figure 7 | Crossing scheme for QF NOT GAL4 intersectional experiments. For the NOT intersectional strategy to work, four components (P1-QF, P2-GAL4, QUAS-geneX and UAS-QS) need to be combined into a fly. In this example, a QF NOT intersectional-ready female fly is represented. This fly contains a P1-QF line recombined with a QUAS-mCD8-GFP marker as well as the UAS-QS transgene on the third chromosome. Crossing this stock with any GAL4 line and selecting against the balancers will result in progeny that have reduced QF expression based on the GAL4 expression pattern. This simplifies the experimental setup for testing the intersectional results for many different GAL4 lines. 
In these examples, QF AND intersectional-ready flies are shown for each strategy. These AND intersectional-ready female flies contain all the necessary components except for the P2-GAL4. Crossing these stocks with any GAL4 line and selecting against the balancers will result in progeny that only have expression where both QF and GAL4 are expressed. These crossing schemes simplify the experimental design required to quickly test many different GAL4 lines for their intersection with a characterized QF line. Although both strategies limit expression to only regions where GAL4 and QF are expressed, they are not equivalent. In a, the resulting expression pattern is determined by the developmental expression pattern of the GAL4 line, and the final expression pattern of the QF line. Conversely, in b, the resulting expression pattern is determined by the developmental expression pattern of the QF line and the final expression pattern of the GAL4 line.
major chromosomes (X, 2nd, 3rd). Each transgenic line should be tested for inducibility and for lack of position effect. Even though most QUAS-geneX insertions are silent without a QF inducer, occasionally a QUAS-geneX line might be expressed because of induction of the minimal hsp70 promoter by local strong enhancer elements. Such lines should be discarded.
Generation of QS effector lines. QS expression can be used to limit QF reporter expression patterns. Similar to the approaches for clon ing QF transgenic animals, a promoter region known to express in defined tissues can be cloned into a QS-SV40 transformation vector (Supplementary Table 1 ). For example, the EcoRI/KpnIflanked tubulin promoter in ptubP-QS-SV40 could be replaced with the promoter of choice. Alternatively, the QS coding region from pBS-KS-QS (that has restriction sites KpnIApaIHindIIIEcoRIQSXbaI NotIEagI) could be cloned into an existing promotercontaining vector of choice.
For QMARCM experiments (Box 1), ubiquitous QS expres sion is required. Lines expressing ubiquitous QS (driven by the tubulin promoter) have been recombined with FRT sites This results in two distinct progeny-one that has an active QF (due to loss of the QS suppressor) and the other that has an active GAL4 (due to loss of the GAL80 suppressor). See Figure 9 for additional details. '*' and 'x' designate two independent mutations that can be rendered homozygous in sister progeny. ;
QUAS-RFP UAS-GFP
Potential applications of the Q system. The Q system can be used for a variety of in vivo applications. In many cases, the experi ment in question will determine which QUAS-geneX effector is used. Table 1 presents a sampling of possible studies, the geneX effectors for QUAS-geneX constructs that might be used, and the method of detection or analysis.
Box 1 | Q-MARCM ExPERIMENTS • tIMInG VARIABLE, DEPENDING oN GENERATIoN oF FLY SToCKS (1-5 GENERATIoNS, ~ 2-10 wEEKS)
MARCM experiments can serve a variety of purposes, including generating mosaic tissues that are mutant for a gene of interest or for identifying the anatomy of a single neuron. Any QF driver line can be used for Q-MARCM experiments (Fig. 9) . The protocol below for performing MARCM experiments is adapted from Nature Protocols
10
. Generate Q-MarcM-ready flies 1. Use standard genetic techniques to introduce the following genetic components into a single fly: (i) FLP recombinase under the control of a heat-shock promoter, (ii) a QUAS-geneX reporter to visualize the Q-MARCM clone, such as QUAS-mCD8-GFP, and (iii) an FRT site and tubP-QS recombined onto the chromosome arm of interest (Fig. 9b) . tubP-QS insertions recombined with FRT sites are available for each major chromosome arm (supplementary table 2).  crItIcal step This balanced stock is a valuable reagent and should be maintained for future experiments. Generate a promoter-QF line that is Q-MarcM ready 2. Use standard genetic techniques to combine a QF line (e.g., GH146-QF) with an FRT chromosome that uses the same FRT site as the Q-MARCM-ready flies generated in the previous step. For example, to be compatible with an 82B
FRT , tubP-QS stock, an 82B FRT line with GH146-QF could be used. The GH146-QF insertion can occur on any chromosome arm.  crItIcal step This balanced stock is a valuable reagent and should be maintained for future experiments.  crItIcal step The promoter-QF insertion can be located distal to the desired FRT (e.g., 82B
FRT , promoter-QF). However, as this chromosome arm will become homozygous after the mitotic recombination event, it might affect the tissue of interest in cases in which the transgene insertion disrupts proper gene functions. It is recommended instead to position the promoter-QF insertion on any other chromosome arm. If possible, recombine the promoter-QF onto the chromosome arm opposite to the used FRT (e.g., promoter-QF, 82B FRT ), which can simplify future MARCM experiments. perform Q-MarcM cross and generate MarcM clones 3. Cross five to ten promoter-QF MARCM-ready males with 10-20 Q-MARCM-ready virgins in a freshly yeasted vial. Depending on the birth date of the tissues of interest, heat shock the progeny in a 37 °C water bath for 30 min to 2 h (see ref. 10 for additional details). For example, to generate olfactory projection neuron clones, a 1.5-h heat-shock procedure can be performed from embryonic to third instar stages. For imaginal wing disc MARCM clones, a 30 min heat-shock procedure is performed at 48 h after egg laying.  crItIcal step The developmental time point and extent of the heat shock needs to be experimentally determined for each target tissue. The Q-MARCM-ready flies often contain an hsFLP insertion on the X chromosome (e.g., Fig. 9b ). Using females of these flies for the Q-MARCM cross will ensure that both male and female progeny will contain Q-MARCM clones. analyze and examine Q-MarcM clones 4. Analyze Q-MARCM clones using an appropriate technique 10 ; live or fixed tissues can be used.
? trouBlesHootInG Table 2 ). In addition, by using a UAS-QS transgenic animal (Supplementary Table 2 ), GAL4 patterns can be used to direct QS expression with the purpose of limiting QF expression patterns (see Step 7B; Fig. 5b ). REAGENT SETUP Quinic acid solution Dissolve quinic acid in water to achieve the desired concen tration; saturated concentration is ~300 mg ml − 1 (roughly equivalent to 1.56 M). The solution may need to be incubated at 37 °C for ~15 min to help dissolve the quinic acid. The solution can be stored as 3.5ml aliquots (makes approxi mately ten quinic acid vials) at − 20 °C for months, but repeated freeze/thaw cycles should be avoided. Propionic acid (0.5% (wt/vol)) In 1liter bottle, mix 5 g of propionic acid with 999 ml of water. This is a stable solution that can be stored for months at room temperature (22-25 °C) . Yeast paste In a small container, mix approximately equal volumes of active dry yeast with 0.5% (wt/vol) propionic acid. Mix with metal spatula until yeast paste has dissolved. Mix in additional dried yeast as needed to achieve creamy peanut butter consistency. Yeast paste should be stored at 4 °C when not in use. The yeast paste in the container should be replaced when it begins to smell sour, usually in ~23 weeks. EQUIPMENT SETUP Quinic acid-containing vials Poke approximately ten holes into the medium of standard fly vials with wooden sticks. Apply ~300 µl of quinic acid solu tion to the medium, making sure all holes are covered. Cover the vials with cotton plugs and allow them to dry on the benchtop overnight. Vials should be used fresh (within 3-4 d if stored at 22-25 °C), but they can be stored at 4 °C for ~2 weeks. (Figs. 1b and 2; table 1 and supplementary table 2) . 2| Depending on the goal of the experiment and the identity of geneX, determine the effect of binary expression on F 1 progeny at an appropriate developmental stage using an appropriate method (see table 1 ). Alternatively, if promoter1-QF and QUAS-geneX are on the same chromosome, you may wish to proceed directly to Step 3 to generate a stable binary expression stock for subsequent analyses. ? trouBlesHootInG Generating a stable binary expression stock • tIMInG 2-3 generations ~25-30 d 3| It is often convenient to recombine the promoter1-QF and QUAS-geneX reporter onto the same chromosome for future expression experiments. This requires that the promoter1-QF and QUAS-geneX are both located on the same chromosome. Common QUAS-geneX reporters are available with insertions on each of the three major chromosomes (supplementary table 2). Choose five to ten virgin F 1 females of genotype promoter1-QF/QUAS-geneX from the progeny in Step 1 and cross with a balancer stock.  crItIcal step To get a successful recombinant, it is essential to use F 1 heterozygote females as meiotic recombination occurs only in females and not in males.
MaterIals
REAGENTS
4| Select a single male progeny that contains both copies of the selectable marker (usually two copies of the mini-white + gene) and set up individual crosses with virgin females from an appropriate balancer stock. Carry out appropriate sib-crosses with the progeny to generate a balanced promoter1-QF/QUAS-geneX stock derived from each original male.  crItIcal step Single males are used for establishing balanced recombinant stocks as recombination does not occur in males. The use of single male crosses ensures that the generated stock will be genetically homogeneous.  crItIcal step If the expression pattern of the promoter1-QF/QUAS-geneX reporter can be visualized in live animals, this expression activity can be used to select for recombinant animals (instead of scoring for both copies of the selectable marker). (Figs. 1, 2 and 4) . To relieve QS suppression of QF during larval development, follow option C. To relieve QS suppression of QF only in adult animals, follow option D. Ubiquitous expression of QS that is linked to a mitotic recombination event can also be used for MARCM (Q-MARCM; Box 1). Coupling both GAL4-based MARCM and Q-based MARCM to the same mitotic event can be used for coupled MARCM (Box 2). with the genotype promoter1-QF/QUAS-geneX promoter2-QS or raise F 1 to adulthood and proceed to Step 6D to relieve QS-mediated suppression of QF using quinic acid. In the former case, in which QS is expressed, the QUAS-geneX reporter will no longer be expressed even if QF is present. As a control, reporter expression without QS presence should also be examined, that is, in parental flies of genotype promoter1-QF/QUAS-geneX.  crItIcal step Promoter2-QS transgenic lines should express QS in the same pattern as promoter2-QF transgenic animals that use the same promoter. This should be verified by crossing the promoter2-QS transgenic fly with a promoter2-QF,QUAS-geneX recombinant fly to confirm that the entire promoter2-QF-reported expression pattern is silenced. Different insertions of the promoter2-QS might need to be tested to find a line that effectively suppresses promoter2-QF.
? trouBlesHootInG (B) expressing Qs in all tissues
(i) Ubiquitous expression of QS can be achieved by using the tubulin promoter to drive QS (tubP-QS). Select an appropriate tubP-QS stock (supplementary table 2) and cross with stable promoter1-QF/QUAS-geneX lines (from Step 4); maintain on standard fly food.
 crItIcal step It is highly recommended to use a promoter1-QF/QUAS-geneX recombinant for ubiquitous QS experiments. As the outcome of tubP-QS experiments is lack of expression, it is vital to know, with 100% certainty, that both promoter1-QF and QUAS-geneX components are present. The lack of either of these components will appear identical to tubP-QS suppression. (ii) Depending on the aim of the experiment, either examine the F 1 progeny for suppression of QF using an appropriate method (table 1) or raise F 1 to adulthood and proceed to Step 6D to relieve QS-mediated suppression of QF using quinic acid. In the former case, the effects of ubiquitous QS expression can be confirmed by the lack of signal from the QUAS-geneX reporter. As a control for effectiveness of tubP-QS, reporter expression of parental flies of genotype promoter1-QF/QUAS-geneX can be examined. ? trouBlesHootInG (c) Quinic acid treatment of developing flies (i) Prepare fresh quinic acid-containing food vials (see REAGENT SETUP).  pause poInt Quinic acid fly food can be stored for up to 2 weeks if kept at 4 °C. (ii) Cross approximately ten tubP-QS animals with approximately ten promoter1-QF/QUAS-geneX animals (from Step 4) and let them lay eggs in quinic acid-containing food vials for 6-12 h. Transfer adults to fresh quinic acid food vials at approximately every 12 h to prevent overcrowding of progeny. The developing larval progeny will ingest sufficient quinic acid for suppression of QS and re-expression of the QUAS-geneX effector (Fig. 1c) .  crItIcal step Alternatively, to target a specific developmental period, crosses could be set up on standard fly food and larvae at the required developmental stages transferred to grape plates or food containing quinic acid.  crItIcal step Quinic acid suppression of QS occurs within ~2 h of animals being placed on quinic acid-containing plates 4 . However, different tissues might respond differently to quinic acid feeding, owing to variations in proliferation rates or the extent of exposure to quinic acid. To reduce the level of quinic acid suppression, lower concentrations of quinic acid solution can be used when generating quinic acid food vials.
(iii) Analyze expression at the appropriate developmental stage using an appropriate technique (table 1) .
? trouBlesHootInG (D) Quinic acid treatment of adult flies (i) Place adults of genotype tubP-QS + promoter1-QF/QUAS-geneX (Step 6B(ii)) in a fresh food vial containing quinic acid solution (Fig. 4) .  crItIcal step Although quinic acid-mediated relief of ubiquitous QS expression is detailed here, tissue-specific promoter2-QS expression can also be relieved by quinic acid treatments, as described above by using flies generated as described in Step 6A.
? trouBlesHootInG (ii) Analyze adult flies for suppression of QS (as monitored by QF-induced QUAS-geneX expression) using an appropriate method (table 1) . Weak suppression of QS is seen within 6 h of being transferred to quinic acid-containing vials, but is most notable within 24 h (ref. Choose option A to use QF expression patterns to limit the extent of GAL4 expression patterns. Choose option B to use GAL4 expression patterns to limit the extent of QF expression patterns. Choose options C or D to limit expression of an effector to only tissues that express both GAL4 and QF transgenes.  crItIcal step Even though the strategies in options C and D reflect the overlapping intersection between QF and GAL4, they are not equivalent. Whichever line is driving FLPase expression will capture the entire developmental profile of that expression pattern, which could be much broader than the expression pattern at the target stage (e.g., the adult stage). The final effector expression level is reflected by whichever transcription factor is driving the final effector transgene (e.g., QF driving QUAS > geneX).
(a) Gal4 not QF intersectional experiments (i) Recombine promoter2-GAL4 and the UAS-geneX onto the same chromosome and generate a balanced stock (as described in Steps 3 and 4 for promoter1-QF and QUAS-geneX).  crItIcal step This balanced stock is a valuable reagent and should be kept for future experiments. (ii) To this promoter2-GAL4/UAS-geneX stock, cross in a QUAS-GAL80 transgene and generate a balanced stock (Fig. 6) .
QUAS-GAL80 transgenes are available on each chromosome (supplementary table 2).  crItIcal step This balanced stock is a valuable reagent and should be kept for future experiments. (iii) Cross a promoter1-QF to the promoter2-GAL4/UAS-geneX; QUAS-GAL80 stock (Fig. 6) . Select progeny that contain all four genetic components required (promoter1-QF, promoter2-GAL4, UAS-geneX and QUAS-GAL80; Fig. 6 and supplementary table 2). As a control, also choose animals that do not contain the QUAS-GAL80 transgene (e.g., select for animals containing the balancer chromosome marked by the Tubby mutation in Fig. 6 ) for analysis.  crItIcal step These genetic components may be located on any chromosome just as long as the progeny contains all four components. The scheme above is designed to simplify the testing of many different promoter-QF lines on altering GAL4 expression patterns. (iv) Analyze UAS-geneX expression using an appropriate technique (table 1) .
 crItIcal step UAS-geneX effector expression will be refined based on the expression pattern of the promoter1-QF. table 2 ) and generate a balanced stock (Fig. 7) .  crItIcal step This balanced stock is a valuable reagent and should be maintained for future experiments. (iii) Cross a promoter2-GAL4 with the promoter1-QF/QUAS-geneX; UAS-QS stock (Fig. 7) . Select progeny that contain all four genetic components required (promoter1-QF, promoter2-GAL4, QUAS-geneX and UAS-QS; Figs. 5b and 7; supplementary table 2). As a control, also choose animals that do not contain the UAS-QS transgene (e.g., select for animals containing the Tubby balancer chromosome in Fig. 7 ) for imaging.
 crItIcal step These genetic components may be located on any chromosome, just as long as the progeny contains all four components. The scheme shown in Figure 7 is designed to simplify the testing of many different promoter-GAL4 lines for their effects on QF expression patterns. (iv) Analyze QUAS-geneX expression using an appropriate technique (table 1) .
 crItIcal step QUAS-geneX effector expression will be refined based on the expression pattern of the promoter2-GAL4. For example, if promoter2-GAL4 is tubulin-GAL4, then there would be no expression of the QUAS-geneX effector. If promoter2-GAL4 overlaps a portion of the promoter1-QF expression pattern, then only the overlapping tissues would no longer express the QUAS-geneX effector (Fig. 5b) . (c) QF anD Gal4 intersectional experiment (developmental profile of promoter-GAL4) (i) Recombine promoter1-QF with a QUAS 'FLP-out' reporter, such as QUAS > stop > mCD8-GFP (supplementary table 2 ) and generate a balanced stock.  crItIcal step This balanced stock is a valuable reagent and should be kept for future experiments. (ii) To the promoter1-QF, QUAS > stop > mCD8-GFP stock, cross in a UAS-FLP transgene and generate a balanced stock (Fig. 8a) .  crItIcal step This balanced stock is a valuable reagent and should be kept for future experiments. (iii) Cross promoter2-GAL4 animals with the promoter1-QF, QUAS > stop > mCD8-GFP; UAS-FLP stock. Select progeny that contain all four genetic components required for QUAS reporter expression (Fig. 8a) . In this case, GAL4 will drive FLPase expression, which will excise the transcription stop from the QUAS > stop > mCD8-GFP effector. QF is then able to induce expression from the resulting QUAS > mCD8-GFP transgene (Fig. 5c) . As a control, also select animals that do not contain the UAS-FLP transgene (e.g., select for animals containing the dominant Tubby mutation, which marks the balancer chromosome in Fig. 8a ) for imaging.  crItIcal step These four genetic components may be located on any chromosome, just as long as the progeny contains all four components. The scheme shown in Figure 8a is designed to simplify the testing of many different promoter-GAL4 lines to determine their overlapping expression pattern with a promoter1-QF line. Unbalanced lines can be used for these experiments, as only when all four components are together will there be any reporter expression. However, using unbalanced lines will reduce the efficiency of the cross and increase the number of animals that need to be processed to ensure a positive result. (iv) Analyze QUAS > mCD8-GFP expression by immunohistochemistry or on live animals by fluorescent microscopy ( (Fig. 8b) .  crItIcal step This balanced stock is a valuable reagent and should be kept for future experiments. (iii) Cross promoter2-GAL4 animals with the promoter1-QF, UAS > stop > mCD8-GFP; QUAS-FLPo stock. Select progeny that contain all four genetic components required for UAS reporter expression (Fig. 8b) . In this case, QF will drive FLPase expression, which will excise the transcription stop from the UAS > stop > mCD8-GFP effector. GAL4 is then able to induce expression from the resulting UAS > mCD8-GFP transgene. As a control, also choose animals that do not contain the QUAS-FLPo transgene (e.g., select for the Tubby animals in Fig. 8b ) for imaging.  crItIcal step These four genetic components may be located on any chromosome just as long as the progeny contains all four components. The scheme shown in Figure 8b is designed to simplify the testing of many different promoter-GAL4 lines to determine their overlapping expression pattern with a promoter1-QF line. Unbalanced lines can be used for these experiments, as only when all four components are together will there be any reporter expression. However, using unbalanced lines will reduce the efficiency of the cross and increase the number of animals that need to be processed to ensure a positive result. (iv) Analyze UAS > mCD8-GFP expression by immunohistochemistry or by using a fluorescent dissecting scope ( • tIMInG
Step 1, ~10 d (1 Fly generation)
Step 2, ~5 d For immunohistochemistry and imaging
Step 3, ~10 d (1 Fly generation) Step 4, 2 Fly generations (~20 d)
Step 5, Variable depending on experimental design; ~5 d if staining and imaging are required
Step 6A, 1 Generation for cross; ~5 d if staining and imaging are required
Step 6B, 1 Generation for cross; ~5 d if staining and imaging are required
Step 6C, 1 Generation for cross; variable depending on extent of quinic acid feeding during development
Step 6D, 1 Generation for cross; adult feeding of quinic acid can continue as long as necessary for the experiment
Step 7A, ~4 Fly generations to generate required stocks; 1 fly generation to perform intersectional experiment; ~5 d for staining and imaging if required
Step 7B, Variable depending on necessity to generate appropriate fly stocks: 1-5 fly generations, and ~5 d for immunohistochemistry and imaging if required
Step 7C, Variable: 1-5 fly generations and ~5 d for imaging
Step antIcIpateD results When a promoter-QF and QUAS-geneX are combined in the same fly, there will be induced expression of geneX. However, when the QUAS-geneX is alone, there will be no effector expression. Figure 1c shows adult flies that contain the QUAS-mtdT-3xHA reporter alone or when combined with a QF enhancer trap line. When the QS suppressor is also introduced, this will block QF activity and keep QUAS-geneX reporters silent. Figure 1c also shows adult flies whose broad QF-induced expression of QUASmtdT-3xHA has been silenced by ubiquitous expression of QS. QS-mediated suppression can itself be inhibited by treating flies with quinic acid. Quinic acid can be fed to developing animals by supplementing their food with quinic acid, and larvae will ingest enough quinic acid for efficient QS suppression in many tissues. Figure 1c shows an adult fly that was previously suppressed by ubiquitous QS but was relieved from such QS suppression by developing on fly food containing quinic acid. Similar quinic acid-mediated re-expression of QF-induced genes can also be carried out in adult animals. By combining the GAL4 and Q systems together, more refined expression patterns can be achieved (Figs. 5 and 11) . These are called intersectional expression experiments, as the final expression pattern depends on the intersection between the QF and GAL4 expression domains. Such intersectional expression experiments could be used to target expression of an effector to a carefully defined target tissue, bypassing confounding effects due to more widespread expression. The outcome of the intersectional experiment depends on the additional genetic components that are used with the promoter1-QF and promoter2-GAL4 lines. By using a UAS-QS transgene, GAL4 expression can be used to effectively limit a QF expression pattern. An example of this QF NOT GAL4 intersection is shown in Figure 11d . Similarly, by using a QUAS-GAL80 transgene, QF expression can be used to effectively limit a GAL4 expression pattern. An example of this GAL4 NOT QF intersection is shown in Figure 11e. A powerful expressional refinement approach is to limit effector expression only to tissues that express both QF and GAL4. An example of this GAL4 AND QF intersection is shown in Figure 11f . This approach can effectively limit effector expression to a very small subset of cells. As the expression pattern of promoter1-QF and promoter2-GAL4 can be easily determined, targeting expression to a desired population of cells only requires picking and choosing the right intersectional combination of GAL4 and QF lines. 
